What is the controversy with Bio-Rad Laboratories?
Bio-Rad Laboratories faced severe regulatory scrutiny and a major federal investigation by the U.S. Securities and Exchange Commission and the Department of Justice regarding violations of the Foreign Corrupt Practices Act (FCPA). Investigations revealed that the company utilized foreign subsidiaries and third-party intermediaries to pay millions of dollars in illicit bribes to government officials in Russia, Vietnam, and Thailand to secure lucrative public healthcare contracts. To resolve these allegations, Bio-Rad agreed to pay a multi-million-dollar financial penalty, implemented rigorous internal compliance remediation programs, and enhanced corporate oversight mechanisms.
Related FAQs
The BMO lawsuit payout refers to the significant legal settlement involving BMO Harris Bank, where it agreed to pay $550 million to resolve litigation brought by a court-appointed receiver related to the Tom Petters Ponzi scheme.
Bio-Rad Laboratories maintains a market capitalization valued at approximately $7.5 billion to $8.4 billion USD.
Bio-Rad Laboratories currently has a dividend yield of 0.0%, as the company does not pay a dividend to its shareholders.
Employee feedback regarding Bio-Rad Laboratories on major professional and career review platforms generally portrays the organization as a stable, respectable employer with an overall average rating hovering around 3.6 out of 5 stars.
Market managers, territory sales managers, and regional commercial leads employed by Pernod Ricard earn comprehensive professional compensation packages that reflect responsibilities in global wine and spirits distribution, brand marketing, and accou...
Bio-Rad Laboratories is widely recognized as a highly reputable, established global leader in the life science research and clinical diagnostics markets.
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics products, making companies with similar business models direct competitors in laboratory instrumentation, assay kits, and life science reagents.
Yes, Bio-Rad Laboratories, Inc. is a publicly traded corporation listed on the New York Stock Exchange under the ticker symbols BIO for its Class A common stock and BIOL for its Class B common stock.
Bio-Rad PCR refers to the polymerase chain reaction instruments, thermal cyclers, reagents, and advanced laboratory systems manufactured by Bio-Rad Laboratories for life science research, genetic analysis, and clinical diagnostics.
Bio-Rad Laboratories operates within the life science research and clinical diagnostics industry.
Yes, Bio-Rad Laboratories is an American multinational corporation headquartered in Hercules, California.
Yes, Bio-Rad Laboratories remains fully operational, active, and highly solvent as a major global leader in life science research and clinical diagnostics.
Bio-Rad maintains its primary U.S. corporate headquarters in Hercules, California, while also operating an extensive footprint of regional offices, distribution centers, and specialized facilities across multiple other states.
Bio-Rad Laboratories, Inc. is headquartered in Hercules, California, United States.
Determining whether Bio-Rad Laboratories (BIO) represents a good stock purchase depends heavily on an investor's time horizon and portfolio strategy.
Companies offering an exceptionally high dividend yield of 10% or more typically operate in specific capital-intensive sectors such as mortgage real estate investment trusts (mREITs), business development companies (BDCs), master limited partnerships...
Biotechnology and biopharmaceutical sector forecasts encompass a vast array of clinical-stage and commercial equities whose individual price predictions depend entirely on pipeline regulatory catalysts, Phase III trial data readouts, and commercial p...
Store managers and retail unit leaders at Boot Barn earn comprehensive compensation packages consisting of competitive base salaries, performance-based cash bonuses, and store sales incentive commissions.
Bio-Rad Laboratories sells a wide-ranging portfolio of life science research products and clinical diagnostic instruments utilized in scientific exploration, healthcare testing, and biopharmaceutical manufacturing.
Bio-Rad Laboratories, a multinational leader in life science research and clinical diagnostic products, officially completed its initial public offering in 1966.
Bio-Rad Laboratories is known for being a global leader in the development, manufacture, and supply of a broad range of innovative products for the life science research and clinical diagnostics markets.
Wall Street financial research analysts tracking Bio-Rad Laboratories (NYSE: BIO) predominantly maintain a consensus "Hold" rating on the stock.
BioMarin Pharmaceutical Inc. maintains a specialized global workforce of approximately 3,221 employees.